Business Wire

Analogix Introduces ANX7441 – First USB-C Re-timer for Next Generation Smartphones and VR Active Cables

Del

Analogix Semiconductor, Inc. today announced the availability of its ANX7441, the first integrated re-timer for next generation smartphones, supporting high bandwidth DisplayPort™ 1.4 at 8.1 gigabits per second (Gbps), as well as USB 3.1 Gen2 10 Gbps data rates over long and thin cables for more flexible virtual reality (VR) applications.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180225005023/en/

ANX7441 is the first USB-C re-timer for next generation smartphones enabling faster communication be ...

ANX7441 is the first USB-C re-timer for next generation smartphones enabling faster communication between mobile devices and 4Kx2K displays ideal for VR applications (Graphic: Business Wire)

For additional cable lengths, Analogix’s ANX7440 re-timer recovers and reinstates high-speed signals at both ends of active cables spanning from 2, 5, and up to 7 meters. This allows low-cost cable solutions to meet the performance and compliance requirements of high-speed DisplayPort and USB 3.1 signals.

Smartphone designs using application processors without an integrated USB-C™ power delivery (PD) port controller can use the ANX7411 companion, which integrates the logic to manage cable attach and detach, orientation, and role detection, providing full USB PD 3.0 support.

“As smartphones adopt high-speed USB-C, the ANX7441 allows next generation application processors to support very high data transfer rates over the USB-C connector, making them ideal for VR applications,” said Michael Ching, vice president of marketing for Analogix. “Human ergonomics are essential to an immersive VR experience and active VR cables using the ANX7440 are longer, thinner, lighter, and capable of delivering video, audio, data, and power from smartphones, PCs, and game consoles to VR HMDs.”

Leveraging Analogix’s competence in high-speed signaling and designed to the latest USB 3.1 and DisplayPort 1.4 specifications, the ANX7441 is cost-effective, low power, and offers best in class performance, supporting:

  • Integrated USB 3.1 re-timer and DisplayPort HBR3 re-timer;
  • Integrated SBU/AUX mux for switching DP AUX signals and reducing overall system BOM cost;
  • Insertion loss compensation to recover up to 23dB channel loss for USB 3.1 Gen2 10 Gbps signals over extended PCB trace and FlexPCB cable.

The ANX7441 is now sampling and will ship in mass production in Q2 2018. The ANX7440 and ANX7411 are in mass production.

Product demonstrations of high-speed signal conditioners, VR active cables, and SlimPort® end-to-end VR solutions are taking place during this week’s Mobile World Congress 2018 at the Analogix booth #7H40 in Hall 7 at Fira Gran Via in Barcelona.

About Analogix Semiconductor

Analogix Semiconductor, Inc. designs and manufactures semiconductors for the digital multimedia market, from portable devices such as smartphones, notebooks, and VR head mounted displays, to large, high-definition TVs and high-end graphics cards. Analogix is the market leader in providing end-to-end interface connectivity semiconductor solutions for DisplayPort under its SlimPort brand, including high-speed signal conditioners, and an industry leader in mobile display controllers, such as low-power, high-speed timing controller solutions. The DisplayPort standard is an innovative, packetized digital interface for high-resolution video and audio that was developed by the Video Electronics Standards Association (VESA). SlimPort branded products are compliant with DisplayPort, Mobility DisplayPort (MyDP), and DisplayPort Alternate Mode over the USB Type-C connector.

For more information visit www.analogix.com and www.slimport.com, follow us on Twitter @Analogix and @SlimPortConnect, or connect with us on LinkedIn.

Analogix and SlimPort are trademarks or registered trademarks of Analogix Semiconductor, Inc. All other trademarks and trade names are the property of their respective owners.

Contact information

Analogix Media Contact
Gratia Stefan, 408-988-8848
marcom@analogix.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Pierre Fabre & Array BioPharma Announce a 62% Observed OS at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO GI Congress23.6.2018 11:00Pressemelding

Not intended for UK- and US-based media Pierre Fabre and its partner Array BioPharma Inc. today announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAF V600E -mutant metastatic colorectal cancer (CRC). The results showed that, at the time of analysis, the OS data were fully mature through 12.6 months and that the median OS had not yet been reached. The one-year overall survival rate for this cohort was 62%. These data were presented in an oral presentation on Saturday, June 23, at the ESMO 20th World Congress on Gastrointestinal Cancer in Barcelona, Spain. The median progression-free survival (mPFS) for patients treated with the triplet was 8 months [95% CI 5.6-9.3] and is similar between patients receiving one prior line of therapy and patients receiving two prior lines

Compelling Data for LONSURF® (trifluridine/tipiracil) in Metastatic Colorectal Cancer Presented at ESMO’s World Congress on Gastrointestinal Cancer by Servier and Taiho23.6.2018 08:10Pressemelding

Servier and Taiho Pharmaceutical Co., Ltd. today announced that the TASCO-1 trial demonstrated promising results for LONSURF® (trifluridine/tipiracil) in combination with bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) who are not suitable for intensive treatment, with a median progression-free survival (PFS) of 9.2 months (ranging from 7.6 to 11.5 months). A second non-comparative arm in the trial, evaluated the outcome of patients treated with the current standard of care of capecitabine in combination with bevacizumab. The median PFS of this arm was 7.8 months (ranging from 5.5 to 10.1 months). “Colorectal cancer is the third most common cancer in the world. While there has been some progress in treatment, there are still few options for patients with metastatic disease who are not suitable for intensive treatment,” said Professor Eric Van Cutsem, Head of Digestive Oncology at the University of Leuven, Belgium. “These compelling results suggest

Softomotive and Accelerate RPA Partner to Help Enterprises Achieve Faster Time to Value from RPA22.6.2018 15:13Pressemelding

Softomotive, a world–class Robotic Process Automation (RPA) technology provider offering best time to value and affordability for all sizes and types of enterprises, is pleased to announce a strategic partnership with AccelerateRPA, a high calibre professional services provider of trained and certified RPA Consultants within Robotic Process Automation. This partnership means that customers and end users of Softomotive’s software, will have additional knowledgeable and professional guidance available to help achieve significant value quickly from their investment in RPA. Companies who are looking to implement Softomotive’s RPA product suite (WinAutomation and ProcessRobot software) will now have direct access to AccelerateRPA’s highly skilled consultants and Developers. Further, AccelerateRPA has also become a licensed reseller of Softomotive’s products, offering customers a single point of contact for delivering both RPA software and services. Ashley Hudson, Director of AccelerateRPA,

Ascend Performance Materials Announces Price Increase for Intermediate Materials22.6.2018 14:00Pressemelding

Ascend Performance Materials announced today a price increase for its intermediate materials. The price increase will take effect globally on July 1, 2018, and includes the following terms: Material Price Increase Terms Hexamethylene diamine (HMD) $0.17/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Acrylonitrile (AN) $0.20/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Customers should contact their local sales representative for additional information. About Ascend Performance Materials Ascend Performance Materials is a global premium provider of high-quality plastics, fibers and chemicals and is the world’s largest integrated producer of PA66 resin. Headquartered in Houston, Texas, Ascend has eight global locations, including five fully-integrated manufacturing facilities located in the southeastern United States, all dedicated to the innovation and safe production of nylon 6,6. With

Different Countries, Different Customs: Get Ready for the Motorbike Holidays with Moto-tyres.co.uk22.6.2018 13:41Pressemelding

Pack your bags, close the boot and get away on holiday? When you start your holidays on a motorcycle, you usually have to consider a few things more when getting ready for your trip. The right preparation is therefore a must. So that nothing stands in the way of a smooth journey, Moto-tyres.co.uk has put together some tips for your next trip. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180622005345/en/ Different countries, different customs: get ready for the motorbike holidays with Moto-tyres.co.uk (Photo: Business Wire) Whether a weekend trip or extended adventure, it all depends on the right equipment. Functional clothing, protectors and rain protection are a must on long trips. Wearing a suitable motorcycle helmet is a legal requirement almost everywhere. However, there are also very different rules and regulations for motorbike equipment and accessories depending on the destination, and you should familiarise yoursel

Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center22.6.2018 12:00Pressemelding

Today Boehringer Ingelheim announced a 230 million euro investment into a new Biologicals Development Center (BDC) at the company’s Research and Development site in Biberach, Germany during the foundation stone laying for the new center. “The BDC is another key building block supporting the company’s long-term strategy for increasing the pipeline’s share of biologicals. This is particularly driven by two of our core areas, immune oncology and immunology,” says Dr. Fridtjof Traulsen, Corporate Senior Vice President Development at Boehringer Ingelheim. “The share of new biological entities in Boehringer Ingelheim’s research pipeline has been consistently increasing over the past few years and has now reached forty percent.” The BDC will help to maximize synergies by integrating biologicals analytical and process development as well as manufacturing for clinical studies into one seamless unit, while at the same time increasing development capacity. Following a staggered launch beginning i